LA JOLLA PHARMACEUTICAL COMPANY LJPC Cash Flow

La jolla pharmaceutical company (LJPC)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities
Net Income (Loss) Attributable to Parent
-93,414	-116,508	-136,693	-158,264	-180,626	-199,469	-192,597	-168,140	-142,091	-114,803	-101,144	-96,107	-84,944	-78,185	-65,131	-54,354	-49,438	-41,912	-36,928	-31,506	-25,140	-21,313	-20,861	-19,983	-18,861	-17,935	-14,643	-12,688	-17,223	-7,737	-17,955	-12,166	245	-11,548	0	0	0
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share-based compensation expense
-	23,733	25,547	29,008	32,460	35,151	35,745	31,347	26,214	21,795	18,918	17,280	15,906	14,546	13,025	12,007	12,268	11,551	11,727	10,669	9,225	8,992	10,400	11,375	11,516	12,373	0	0	0	-	-	-	-	254	0	0	0
Third party share-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	675	829	1,107	1,521	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third party share-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain on adjustment to fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,998	0	0	0	-	-	-	-
Depreciation and amortization expense
4,482	4,552	4,568	4,580	4,543	4,405	3,614	2,775	1,979	1,268	1,119	1,001	869	730	648	562	478	347	216	107	26	17	12	9	7	5	0	0	0	-	-	-	-	-	-	-	-
Loss on disposal of equipment
-157	-24	-15	-101	-119	-236	-435	-349	-331	-199	0	0	-54	-75	-91	-91	-37	-16	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
8,147	8,775	9,347	9,820	9,107	6,797	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash rent expense
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable, net
1,553	1,579	-120	1,521	1,999	1,381	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory, net
-17	191	809	1,029	1,157	2,020	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash, current portion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37	163	163	200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid clinical expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	360	458	1,449	1,528	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
(Gain) loss on adjustments to fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Prepaid expenses and other current assets
-1,756	-644	-1,064	-193	-1,187	1,964	4,075	3,507	4,639	1,642	271	232	215	664	-511	-607	-678	-824	331	474	466	94	106	81	80	18	7	-30	26	-35	31	78	48	-7	0	0	0
Other assets
-	-	-	-	-	-	-	-	-	-219	-219	-217	-197	149	162	160	160	70	57	57	57	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-1,146	-4,395	-1,232	-1,161	-4,280	-2,912	331	149	3,148	4,832	3,695	3,118	1,219	3,600	-23	959	495	2,322	1,884	926	1,897	-104	269	757	424	742	325	49	-4	-49	0	0	0	-	-	-	-
Accrued expenses
-2,751	395	-787	1,817	2,616	5,451	5,938	4,947	3,814	-202	-2,700	-1,202	-1,399	227	2,226	1,281	1,748	-248	245	227	-145	739	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accrued payroll and related expenses
1,613	823	196	-538	-1,008	2,514	1,694	2,755	2,134	2,918	1,907	1,068	558	987	692	385	352	666	597	289	-109	324	-51	53	56	56	0	0	0	-	-	-	-	-78	0	0	0
Lease liability
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	824	1,445	1,711	1,023	335	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used for operating activities
-64,513	-84,950	-99,854	-118,148	-139,204	-152,368	-145,687	-127,270	-108,887	-85,081	-78,337	-74,856	-67,750	-58,709	-48,579	-39,026	-32,677	-25,183	-22,106	-19,436	-15,659	-12,879	-9,544	-7,894	-6,758	-4,734	-3,123	-2,426	-2,181	-2,135	-2,139	-1,986	-2,364	-1,826	0	0	0
Investing activities
Proceeds from the sale of property and equipment
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
514	698	767	900	1,530	2,340	7,158	9,054	9,438	9,194	5,087	3,329	2,490	2,218	1,554	1,401	1,903	1,816	1,853	1,527	634	258	89	61	58	43	0	0	0	-	-	-	-	-	-	-	-
Purchase of patent assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by (used for) investing activities
629	-698	-767	-900	-1,530	-2,340	-7,158	-9,054	-9,438	-9,194	-5,087	-3,329	-2,490	-2,218	-1,554	-1,401	-1,903	-1,816	-1,853	-1,527	-634	-258	-89	-61	-58	-43	0	0	0	-	-	-	-	-	-	-	0
Financing activities
Proceeds from the issuance of common stock under ESPP
-	833	1,052	875	674	391	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of common stock under 2013 Equity Plan
-	31	0	192	1,380	1,908	2,242	2,335	1,147	2,693	2,423	2,138	2,138	149	113	343	343	315	287	57	57	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from the issuance of common stock
-	-	-	-	-	109,809	109,809	109,809	109,809	117,480	117,480	117,480	117,480	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
1,086	864	1,052	1,067	126,343	236,397	236,340	236,433	110,956	120,173	119,903	119,618	119,618	149	113	104,939	104,939	104,911	104,883	53,120	53,120	53,063	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and restricted cash
-62,798	-84,784	-99,569	-117,981	-14,391	81,689	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of non-cash investing and financing activities:
Conversion of Series F Convertible Preferred Stock into common stock
0	2,737	2,737	2,737	2,737	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Initial recognition of right-of-use lease asset
0	16,798	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciliation of cash and restricted cash to the consolidated balance sheets
Reconciliation of cash and restricted cash to the condensed consolidated balance sheets
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-50,020	64,512	70,359	77,912	80,924	32,157	36,827	39,926	43,431	2,046	3,185	5,224	7,337	-1,964	-1,681	-1,635	-2,139	-1,986	-2,121	-1,826	0	0	0
Conversion of Series C-1 and D-1 Preferred Stock into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,531	0	0	0
Suspension of preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0